The SILCS diaphragm is a single-size contraceptive barrier designed to fit a broad range of women. This document describes product features and the steps that PATH and our commercialization partner, Kessel Marketing & Vertriebs GmbH, are taking as we build toward the introduction of SILCS in low-resource settings.

Publication date: June 2013

Region: Global

This report covers a 2009 consultation in Kampala, Uganda, that was convened by the Global Campaign for Microbicides, the Joint UN Programme on HIV/AIDS, and the US Centers for Disease Control and Prevention. It includes recommendations related to key ethical and practical questions on the design and implementation of clinical trials.

Author: McGrory E, Philpott S, Hankins C, Paxton L, Heise L

Publication date: May 2010

Region: Global

This website about the technologies for reproductive health work within the Technology Solutions program provides an overview of the group and its featured projects. See other PATH program websites.

Publication date: 2013

Region: Global

Part of series: PATH's program websites

This website about PATH’s Technology Solutions global program provides an overview of the program and its featured projects. See other PATH program websites.

Publication date: 2013

Region: Global

Part of series: PATH's program websites

This fact sheet provides an overview of PATH's work to adapt, design, develop, and advance health technologies to improve global health.

Publication date: December 2011

Region: Global

Part of series: PATH's areas of focus fact sheets

This brief summarizes key findings from a literature review conducted by PATH to identify published and gray literature reporting international experiences with the Uniject™ injection system. The findings shed light on user acceptability and highlight potential cost savings in terms of training time, waste management, and reduction in drug wastage when Uniject is used instead of a standard autodisable syringe. This document synthesizes the experience and evidence on the use of Uniject worldwide with medicines such as the injectable contraceptive Cyclofem®, hepatitis B and tetanus toxoid vaccines, as well as the drug oxytocin, which is used to prevent postpartum hemorrhage.

Publication date: February 2011

Region: Global

Part of the Technology Updates series, this fact sheet describes the Woman's Condom project at PATH.

Publication date: July 2013

Region: Global

Part of series: Technology Updates

The Woman’s Condom is a new female condom designed to protect women and couples from unintended pregnancy and sexually transmitted infections and to be highly pleasurable. This document describes product features and the steps that PATH and our manufacturing partner, Shanghai Dahua Medical Apparatus Company, are taking to raise awareness and build demand. The Woman’s Condom is branded O’lavie™ in China.

Publication date: April 2013

Region: Global

The Woman's Condom is a new female condom that has been evaluated for acceptability, performance, and safety in clinical studies across five countries. This document summarizes key findings from completed clinical studies and provides updates on clinical studies in process.

Publication date: February 2013

Region: Global